PHILADELPHIA – A compound found in soybeans almost completely prevented the spread of human prostate cancer in mice, according to a study published in the March 15 issue of Cancer Research, a journal of the American Association for Cancer Research.
Researchers say that the amount of the chemical, an antioxidant known as genistein, used in the experiments was no higher than what a human would eat in a soybean-rich diet.
Investigators from Northwestern University found that genistein decreased metastasis of prostate cancer to the lungs by 96 percent compared with mice that did not eat the compound in their chow - making the study the first to demonstrate genistein can stop prostate cancer metastasis in a living organism.
“These impressive results give us hope that genistein might show some effect in preventing the spread of prostate cancer in patients,” said the study’s senior investigator, Raymond C. Bergan, MD, director of experimental therapeutics for the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
“Diet can affect cancer and it doesn’t do it by magic,” Bergan said. “Certain chemicals have beneficial effects and now we have all the preclinical studies we need to suggest genistein might be a very promising chemopreventive drug.”
Bergan and his team have previously demonstrated in prostate cancer cell cultures that genistein inhibits detachment of cancer cells from a primary prostate tumor and represses cell invasion. It does this by blocking activation of p38 MAP kinases, molecules which regulate pathways that activate proteins that loosen cancer cells from their tight hold within a tumor, pushing them to migrate.
“In culture, you can actually see that when genistein is introduced, cells flatten themselves in order to spread out and stick strongly to nearby cells,” he said.
In this study, investigators fed genistein to several groups of mice before implanting them with an aggressive form of prostate cancer .The amount of genistein in the blood of the animals was comparable to human blood concentrations after consumption of soy foods, Bergan said.
The researchers found that while genistein didn’t reduce the size of tumors that developed within the prostate, it stopped lung metastasis almost completely. They repeated the experiment and found the same result.
They then examined tissue in the animals, measuring the size of tumor cells’ nuclei to determine if the cells had flattened out in order to spread. “Within a tumor, it is hard to tell where the borders of cells stop, so one way to measure adherence is to look at the size of the nuclei in cells and see if they are wider due to cell spread,” Bergan said. “And that is what we found, demonstrating that the drug is having a primary effect on metastasis.”
He said that the study also found that mice fed genistein expressed higher levels of genes that are involved in cancer cell migration which, Bergan says, at first might not make sense in light of the study’s conclusion that genistein almost completely blocked metastasis.
“What we think is happening here is that the cells we put in the mice normally like to move. When genistein restricted their ability to do so, they tried to compensate by producing more protein involved in migration. But genistein prevented those proteins from being activated,” he said. “This is really a lesson for researchers who depend on biomarker studies to test whether a treatment is working. They need to be aware that those biomarkers might be telling only half of the story.”
Bergan cautioned that much is unknown about use of genistein in preventing cancer spread. For example, it may be that the effects of the compound in people who have eaten soy all their lives is stronger than benefit seen in patients who have only started to use genistein.
Grand Forks Human Nutrition Research Center, Agricultural Research Service, US Department of Agriculture, Grand Forks, ND, and the Department of Mathematics, Washington University, St Louis, MO.
BACKGROUND: Epidemiologic studies have shown that the consumption of soy foods may be associated with a reduction in cancer risk in humans.
OBJECTIVE: The purpose of this study was to conduct a meta-analysis on the association between soy consumption and prostate cancer risk in men.
DESIGN: We systematically reviewed studies obtained through a thorough Medline literature search and identified 15 epidemiologic publications on soy consumption and 9 on isoflavones in association with prostate cancer risk. We extracted the most adjusted relative risks (RRs) and odds ratios (ORs) of the highest and the lowest reported categories of intake from each study and conducted this analysis using a random-effects model in which studies with smaller SEEs are given greater weight in the summary measure.
RESULTS: Our analysis of studies on soy intake yielded a combined RR/OR of 0.74 (95% CI: 0.63, 0.89; P = 0.01). When separately analyzed, studies on nonfermented soy foods yielded a combined RR/OR of 0.70 (95% CI: 0.56, 0.88; P = 0.01) and those on fermented soy foods yielded a combined RR/OR of 1.02 (95% CI: 0.73, 1.42; P = 0.92). The analysis of studies on isoflavones yielded a combined RR/OR of 0.88 (95% CI: 0.76, 1.02; P = 0.09). Further separate analyses showed a combined RR/OR of 0.52 (95% CI: 0.34, 0.81; P = 0.01) from studies with Asian populations and 0.99 (95% CI: 0.85, 1.16; P = 0.91) from studies with Western populations.
CONCLUSIONS: The results of this analysis suggest that consumption of soy foods is associated with a reduction in prostate cancer risk in men. This protection may be associated with the type and quantity of soy foods consumed.
Soy Compound May Fight Prostate Cancer
Linear Mode
